When Rian Johnson’s Knives Out first hit theaters, it wasn’t just a clever whodunit with an all-star ensemble cast. It was the birth of a new franchise, and an instantly iconic sleuth in Daniel ...

I’m glad you asked. Mostly because it gives me a chance to make fun of Notre Dame. Here now is my attempt to explain the dispute as best I can. Don’t expect miracles. The Fighting Irish last won a ...

"Wake Up Dead Man: A Knives Out Mystery" is the latest installment in Rian Johnson's murder-mystery franchise. Daniel Craig returns as detective Benoit Blanc alongside a new ensemble cast including ...

Fog is a quintessential part of the Bay Area, a seemingly simple suspension of water in air that has shaped our culture and ecology since time immemorial. For us, it is the ghostly embodiment of cold ...

St. Paul's choirmaster Jack Cleghorn is a lifelong choir kid. But this holiday season, he gets to share his not-so-secret-passion for conducting. Cleghorn, who is also the organist for the historic ...

A whodunit is a bit like a basketball game: The last few minutes are all that really matter. Still, writer-director Rian Johnson managed to pump some life into a largely forgotten cinematic genre with ...

With Rian Johnson’s killer murder mystery Wake Up Dead Man coming this holiday season, there’s no better time than now to take stock of the characters we’ve met over the last couple outings. From the ...

Billy Bob Thornton opened up about the challenges he faced as a southerner trying to make it in Hollywood during the early years of his career. While appearing alongside his "Landman" co-star Sam ...

Billy Bob Thornton still believes Hollywood looks down on people from the South. During an appearance on Joe Rogan's podcast, Thornton lit a cigarette and said there was a "prejudice" when he first ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago. These ...

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP ...